XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1Close
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue $ 1,000 $ 0 Close
Operating expenses:    
Research and development 2,649 3,942
General and administrative 3,978 3,485
Total operating expenses 6,627 7,427 Close
Operating loss (5,627) (7,427) Close
Interest income 79 100 Close
Total Other Income Expenses 79.0 100.0 0 0 0 Close Close
Loss before income taxes and noncontrolling interest (5,919) (5,774) CloseClose
Income tax provision 100 0
Net loss before noncontrolling interest (6,019) (5,774)
Less: net loss attributable to noncontrolling interest (1,154) (1,275)
Net loss attributable to vTv Therapeutics Inc. (4,865) (4,499)
Net loss attributable to vTv Therapeutics Inc. common shareholders (4,865) (4,499)
Nonrelated Party    
Operating expenses:    
Other income, net 0 1,791 Close
Related Party    
Operating expenses:    
Other income, net $ (371) $ (238)
Class A Common Stock    
Operating expenses:    
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (in usd per share) [1] $ (1.17) $ (2.16) Close
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (in usd per share) [1] $ (1.17) $ (2.16)
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares) [1] 4,141,492 2,084,973
Weighted-average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares) [1] 4,141,492 2,084,973
[1]
(*) Adjusted retroactively for reverse stock split